TuHURA Biosciences filings document regulatory disclosures for a Nasdaq-listed clinical-stage immuno-oncology company. Recent 8-K reports cover operating and financial results, corporate updates on IFx-2.0, TBS-2025 and early-stage ADC programs, and material agreements tied to development funding and general corporate purposes.
The filing record also includes capital-structure disclosures for common stock, warrants, shelf and resale registration matters, secured borrowing arrangements, governance matters and Nasdaq continued-listing compliance. These documents describe the company's registered common stock, financing instruments, material-event reporting and formal updates on its cancer-immunotherapy development programs.
TuHURA Biosciences' amended S-1 (S-1/A) describes a clinical-stage biopharma focused on innate and tumor microenvironment immunotherapies. The filing notes initiation of a Phase 3 trial of IFx-2.0 in June 2025 using the FDA accelerated approval pathway and reports prior early-stage data: 23 patients enrolled in an IFx-2.0 study with no grade 3+ toxicities, a recommended Phase 2 dose, a 48% disease control rate at injected lesions at 28 days and a post-protocol objective response rate of 64% (7 of 11) in Merkel cell carcinoma after ICI rechallenge. TuHURA acquired Kineta assets including TBS-2025 (VISTA antibody) in June 2025 and plans a randomized Phase 2 in mutNPM1 AML (menin inhibitor ± TBS-2025) to start in late Q4 2025. Financial disclosures state the company has no product revenue, substantial operating losses, a going concern qualification and material non-cash charges (~$16.9M, including a $16.2M IPR&D write-off). The S-1/A also details a prior merger transaction structure and executive employment and compensation terms.
TuHURA Biosciences' amended S-1 (S-1/A) describes a clinical-stage biopharma focused on innate and tumor microenvironment immunotherapies. The filing notes initiation of a Phase 3 trial of IFx-2.0 in June 2025 using the FDA accelerated approval pathway and reports prior early-stage data: 23 patients enrolled in an IFx-2.0 study with no grade 3+ toxicities, a recommended Phase 2 dose, a 48% disease control rate at injected lesions at 28 days and a post-protocol objective response rate of 64% (7 of 11) in Merkel cell carcinoma after ICI rechallenge. TuHURA acquired Kineta assets including TBS-2025 (VISTA antibody) in June 2025 and plans a randomized Phase 2 in mutNPM1 AML (menin inhibitor ± TBS-2025) to start in late Q4 2025. Financial disclosures state the company has no product revenue, substantial operating losses, a going concern qualification and material non-cash charges (~$16.9M, including a $16.2M IPR&D write-off). The S-1/A also details a prior merger transaction structure and executive employment and compensation terms.